GlaxoSmithKline (GSK) Stock Rating Reaffirmed by Barclays
GlaxoSmithKline (LON:GSK)‘s stock had its “overweight” rating reissued by research analysts at Barclays in a research report issued on Friday. They currently have a GBX 1,650 ($23.14) target price on the stock. Barclays’ price target would suggest a potential upside of 27.81% from the stock’s previous close.
Other equities research analysts have also issued research reports about the stock. Investec lowered shares of GlaxoSmithKline to a “hold” rating and reduced their price objective for the company from GBX 1,800 ($25.24) to GBX 1,390 ($19.49) in a research note on Monday, November 6th. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Jefferies Group reduced their price objective on shares of GlaxoSmithKline from GBX 1,700 ($23.84) to GBX 1,540 ($21.59) and set a “buy” rating for the company in a research note on Tuesday, October 31st. UBS Group set a GBX 1,550 ($21.73) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a report on Thursday. Finally, Berenberg Bank dropped their target price on shares of GlaxoSmithKline from GBX 1,760 ($24.68) to GBX 1,705 ($23.91) and set a “buy” rating on the stock in a report on Thursday. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,541.36 ($21.61).
Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,291 ($18.10) on Friday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($17.32) and a 52 week high of GBX 1,724.50 ($24.18). The stock has a market cap of $64,010.00 and a price-to-earnings ratio of 4,164.52.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.